首页> 美国卫生研究院文献>Drug Delivery >Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment
【2h】

Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment

机译:细胞穿透肽功能化藤黄酸-纳米结构脂质载体治疗癌症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor-targeted delivery is considered a crucial component of current anticancer drug development and is the best approach to increase the efficacy and reduce the toxicity. Nanomedicine, particularly ligand-based nanoparticles have shown a great potential for active targeting of tumor. Cell penetrating peptide is one of the promising ligands in a targeted cancer therapy. In this study, the gambogic acid-loaded nanostructured lipid carrier (GA-NLC) was modified with two kinds of cell penetrating peptides (cRGD and RGERPPR). The GA-NLC was prepared by emulsification and solvent evaporation method and coupled with cRGD, RGERPPR, and combination cRGD and RGERPPR to form GA-NLC-cRGD, GA-NLC-RGE, and GA-NLC-cRGD/RGE, respectively. The formulations were characterized by their particle size and morphology, zeta potential, encapsulation efficiency, and differential scanning calorimetry. In vitro cytotoxicity and cellular uptake study of the formulations were performed against breast cancer cell (MDA-MB-231). Furthermore, in vivo biodistribution and antitumor activity of the formulations were determined by in vivo imaging and in tumor-bearing nude mice, respectively. The result of in vitro cytotoxicity study showed that GA-NLC-RGE exhibited a significantly higher cytotoxicity on MDA-MB-231 as compared with GA-NLC and GA-Sol. Similarly, RGE-Cou-6-NLC showed remarkably higher uptake by the cells than other NLCs over the incubation period. The in vivo imaging study has demonstrated that among the formulations, the RGE-decorated DiR-NLC were more accumulated in the tumor site. The in vivo antitumor activity revealed that RGE-GA-NLC inhibits the tumor growth more efficiently than other formulations. In conclusion, RGERPPR has a potential as an effective carrier in targeting drug delivery of anticancer agents.
机译:靶向肿瘤的递送被认为是当前抗癌药物开发的关键组成部分,并且是提高疗效和降低毒性的最佳方法。纳米医学,特别是基于配体的纳米颗粒已经显示出巨大的潜力,可以有效地靶向肿瘤。细胞穿透肽是靶向癌症治疗中有希望的配体之一。在这项研究中,用两种细胞穿透肽(cRGD和RGERPPR)修饰了装载了藤黄酸的纳米结构脂质载体(GA-NLC)。 GA-NLC是通过乳化和溶剂蒸发法制备的,并与cRGD,RGERPPR以及cRGD和RGERPPR结合使用,分别形成GA-NLC-cRGD,GA-NLC-RGE和GA-NLC-cRGD / RGE。该制剂的特征在于其粒径和形态,ζ电势,包封效率和差示扫描量热法。该制剂针对乳腺癌细胞(MDA-MB-231)进行了体外细胞毒性和细胞摄取研究。此外,分别通过体内成像和在荷瘤裸鼠中确定制剂的体内生物分布和抗肿瘤活性。体外细胞毒性研究的结果表明,与GA-NLC和GA-Sol相比,GA-NLC-RGE对MDA-MB-231表现出明显更高的细胞毒性。同样,在孵育期间,RGE-Cou-6-NLC的细胞摄取显着高于其他NLC。体内成像研究表明,在这些制剂中,装饰有RGE的DiR-NLC在肿瘤部位更多地积累。体内抗肿瘤活性表明,RGE-GA-NLC比其他制剂更有效地抑制肿瘤生长。总之,RGERPPR作为靶向抗癌药物的有效载体具有潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号